Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ingenol Mebutate

FDA-approved product (gel, topical), marketed as Ingenol Mebutate, Picato.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Ingenol Mebutate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Actinic keratosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other chemotherapeutics
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC D06BX02

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli32.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis37.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ingenol Mebutate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ingenol Mebutate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluation of Ingenol Mebutate for Actinic Cheilitis Treatment

    NCT03452566 · start 2020-02

    Registered record
    Registry ID
    NCT03452566
    Conditions
    Actinic Cheilitis
    Interventions
    Ingenol mebutate gel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2020-02
    Completion
    2022-04
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActinic Cheilitis
    InterventionIngenol mebutate gel
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • Basal Cell Carcinomas Treated With Ablative Fractional Laser and Ingenol Mebutate

    NCT03569345 · start 2017-11-17

    Registered record
    Registry ID
    NCT03569345
    Conditions
    Carcinoma, Basal Cell
    Interventions
    AFXl-assisted ingenol mebutate delivery
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2017-11-17
    Completion
    2018-05-18
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Basal Cell
    InterventionAFXl-assisted ingenol mebutate delivery
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Efficacy of Ingenol Mebutate on Actinic Keratoses and Field Cancerization vs Cryotherapy

    NCT02990221 · start 2017-04-12

    Registered record
    Registry ID
    NCT02990221
    Conditions
    Actinic Keratosis
    Interventions
    Ingenol mebutate; cryotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-04-12
    Completion
    2018-07-30
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActinic Keratosis
    InterventionIngenol mebutate; cryotherapy
    PhasePhase 4
    Registry statusCompleted

  • Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients

    NCT02866695 · start 2016-10-06

    Registered record
    Registry ID
    NCT02866695
    Conditions
    Actinic Keratosis
    Interventions
    ingenol mebutate gel 0.015%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-10-06
    Completion
    2018-07-02
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActinic Keratosis
    Interventioningenol mebutate gel 0.015%
    PhasePhase 4
    Registry statusCompleted

  • An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis

    NCT03200912 · start 2016-08-19

    Registered record
    Registry ID
    NCT03200912
    Conditions
    ACTINIC KERATOSIS
    Interventions
    Ingenol Mebutate (Picato®); Generic Ingenol Mebutate; Vehicle Foam
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-08-19
    Completion
    2017-03-22
    Enrolment
    507

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionACTINIC KERATOSIS
    InterventionIngenol Mebutate (Picato®); Generic Ingenol Mebutate; Vehicle Foam
    PhasePhase 3
    Registry statusCompleted

  • Prospective Study of Ingenol Mebutate for Non-invasive Lentigo Melanoma of the Face

    NCT02723721 · start 2016-06-15

    Registered record
    Registry ID
    NCT02723721
    Conditions
    Lentigo Maligna
    Interventions
    Picato gel
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-06-15
    Completion
    2020-01-27
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLentigo Maligna
    InterventionPicato gel
    PhasePhase 2
    Registry statusCompleted

  • Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands.

    NCT02748902 · start 2016-04-27

    Registered record
    Registry ID
    NCT02748902
    Conditions
    Verruca Vulgaris; Common Warts
    Interventions
    ingenol mebutate 0.05% gel
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-04-27
    Completion
    2017-03-30
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVerruca Vulgaris; Common Warts
    Interventioningenol mebutate 0.05% gel
    PhasePhase 1
    Registry statusCompleted

  • The Use of Picato® (Ingenol Mebutate) to Treat Actinic Keratosis in Standard Clinical Practice

    NCT02594436 · start 2015-12-01

    Registered record
    Registry ID
    NCT02594436
    Conditions
    Actinic Keratosis
    Interventions
    Ingenol mebutate
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-12-01
    Completion
    2017-11
    Enrolment
    440

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActinic Keratosis
    InterventionIngenol mebutate
    PhaseNot recorded
    Registry statusCompleted

  • Clinical and Histologic Evaluation of Picato 0.15% Gel in the Cosmetic Improvement of Photoaged Skin

    NCT03508856 · start 2015-11-09

    Registered record
    Registry ID
    NCT03508856
    Conditions
    Actinic Keratosis; Photo-aged Skin
    Interventions
    Ingenol Mebutate (Picato®) 0.015% gel
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-11-09
    Completion
    2016-08-09
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActinic Keratosis; Photo-aged Skin
    InterventionIngenol Mebutate (Picato®) 0.015% gel
    PhaseNot applicable
    Registry statusCompleted

  • Ingenol Mebutate Gel 0.05% in Kidney Transplant Recipients With Actinic Keratoses

    NCT02473848 · start 2015-06

    Registered record
    Registry ID
    NCT02473848
    Conditions
    Actinic Keratosis
    Interventions
    ingenol mebutate 500 ucg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2015-06
    Completion
    2017-12
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActinic Keratosis
    Interventioningenol mebutate 500 ucg
    PhasePhase 3
    Registry statusTerminated

  • To Compare Safety and Efficacy of Perrigo's Drug Compared to an FDA Approved Drug in the Treatment of Actinic Keratosis

    NCT02459795 · start 2015-05

    Registered record
    Registry ID
    NCT02459795
    Conditions
    Actinic Keratosis
    Interventions
    Ingenol Mebutate (Perrigo); Ingenol Mebutate (Reference); Placebo gel
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-05
    Completion
    2015-12
    Enrolment
    469

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActinic Keratosis
    InterventionIngenol Mebutate (Perrigo); Ingenol Mebutate (Reference); Placebo gel
    PhasePhase 3
    Registry statusCompleted

  • Clinical Trial of Ingenol Mebutate Gel 0.015% & 0.05% in Actinic Keratosis

    NCT02716714 · start 2015-04

    Registered record
    Registry ID
    NCT02716714
    Conditions
    Actinic Keratosis
    Interventions
    ingenol mebutate gel 0.015%; ingenol mebutate gel 0.05%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-04
    Completion
    2016-06
    Enrolment
    77

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActinic Keratosis
    Interventioningenol mebutate gel 0.015%; ingenol mebutate gel 0.05%
    PhasePhase 4
    Registry statusCompleted

  • Treatment of Actinic Keratoses (AK) on the Face

    NCT02411851 · start 2015-03

    Registered record
    Registry ID
    NCT02411851
    Conditions
    Actinic Keratoses
    Interventions
    ingenol mebutate 0.015%; dermasil lotion
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-03
    Completion
    2016-06
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActinic Keratoses
    Interventioningenol mebutate 0.015%; dermasil lotion
    PhasePhase 1
    Registry statusCompleted

  • Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts

    NCT02377999 · start 2015-02

    Registered record
    Registry ID
    NCT02377999
    Conditions
    Anogenital Warts
    Interventions
    Picato
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-02
    Completion
    2015-11
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnogenital Warts
    InterventionPicato
    PhasePhase 2
    Registry statusCompleted

  • To Compare Safety and Efficacy of Perrigo's Drug Product Compared to an FDA Approved Drug Product in the Treatment of Actinic Keratosis

    NCT02385318 · start 2015-02

    Registered record
    Registry ID
    NCT02385318
    Conditions
    Actinic Keratosis
    Interventions
    Ingenol Mebutate (Perrigo); Ingenol Mebutate (Reference); Placebo gel
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-02
    Completion
    2015-12
    Enrolment
    519

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionActinic Keratosis
    InterventionIngenol Mebutate (Perrigo); Ingenol Mebutate (Reference); Placebo gel
    PhasePhase 3
    Registry statusCompleted